Fungal Infection Clinical Trial
Official title:
The Impact of Rapid Diagnostic Methods in the Diagnosis of Fungal Infections in Intensive Care Units of Assiut University Hospital
Verified date | July 2023 |
Source | Assiut University |
Contact | sara salah |
Phone | 01092127787 |
fawazsara91[@]gmail.com | |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The diagnosis of invasive fungal disease remains challenging in the clinical laboratory. The use of matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS) for the identification of filamentous fungi as well as its application for antifungal resistance testing and strain typing Will be evaluated.
Status | Not yet recruiting |
Enrollment | 100 |
Est. completion date | December 2024 |
Est. primary completion date | May 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Patients of all age group and both sex with clinically suspected fungal infection at intensive care units of Assiut university hospital will be included. Exclusion Criteria: - -Patients who are on antifungal treatment and refuse to take part will be excluded from the study. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Assiut University |
Colombo AL, de Almeida Junior JN, Slavin MA, Chen SC, Sorrell TC. Candida and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer. Lancet Infect Dis. 2017 Nov;17(11):e344-e356. doi: 10.1016/S1473-3099(17)30304-3. Epub 2017 Jul 31. — View Citation
Mayer FL, Wilson D, Hube B. Candida albicans pathogenicity mechanisms. Virulence. 2013 Feb 15;4(2):119-28. doi: 10.4161/viru.22913. Epub 2013 Jan 9. — View Citation
Neppelenbroek KH, Seo RS, Urban VM, Silva S, Dovigo LN, Jorge JH, Campanha NH. Identification of Candida species in the clinical laboratory: a review of conventional, commercial, and molecular techniques. Oral Dis. 2014 May;20(4):329-44. doi: 10.1111/odi.12123. Epub 2013 May 16. — View Citation
Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. Nat Rev Dis Primers. 2018 May 11;4:18026. doi: 10.1038/nrdp.2018.26. — View Citation
Vandeputte P, Ferrari S, Coste AT. Antifungal resistance and new strategies to control fungal infections. Int J Microbiol. 2012;2012:713687. doi: 10.1155/2012/713687. Epub 2011 Dec 1. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Phenotypically identify percentage of different fungal infections isolated from various clinical specimens in intensive care units. and Assess their antifungal susceptibility pattern. | Assess the accuracy of Maldi-TOF in diagnosis of fungal infections | baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03641131 -
Ampholipad Real-World Data in Taiwan
|
||
Not yet recruiting |
NCT03292224 -
Systemic Fungal Infections in ICU Patients
|
N/A | |
Completed |
NCT01371656 -
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
|
Phase 3 | |
Completed |
NCT00936117 -
Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia
|
Phase 2 | |
Completed |
NCT00740389 -
TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.
|
Phase 1 | |
Completed |
NCT03857399 -
Empiric Therapy of Patients With Persistent Fever and Agranulocytosis Using Caspofungin
|
Phase 2 | |
Not yet recruiting |
NCT04215458 -
Microbiota in Skin and Mucosa of Patients With Inflammatory Skin Diseases
|
N/A | |
Completed |
NCT03667690 -
Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
|
Phase 3 | |
Completed |
NCT02957929 -
Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally
|
Phase 1 | |
Completed |
NCT01419678 -
Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients
|
N/A | |
Recruiting |
NCT00333645 -
Prophylaxis With Caspofungin in High-Risk Liver Transplantation
|
Phase 2 | |
Not yet recruiting |
NCT03650439 -
Fungal Infections in Patients With Hematological Malignancies
|
||
Completed |
NCT01303549 -
Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients
|
Phase 4 | |
Withdrawn |
NCT00430469 -
Safety of hLF1-11 for the Treatment of Infectious Complications Among HSCT Recipients
|
Phase 1/Phase 2 | |
Completed |
NCT00811642 -
Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551)
|
Phase 3 | |
Terminated |
NCT00386997 -
ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia
|
Phase 4 | |
Completed |
NCT00514358 -
Fluconazole Pharmacokinetics in Infants
|
Phase 1 | |
Completed |
NCT04166669 -
A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001
|
Phase 1 | |
Recruiting |
NCT05150327 -
Multicenter Cohort Study of Invasive Fungal Filamentous Fungal Infections in Liver Transplant Patients
|
||
Completed |
NCT02387983 -
Pharmacokinetics and Safety of Oral Posaconazole (MK-5592)Tablets in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-117)
|
Phase 1 |